

## **BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21<sup>st</sup> Annual Health Care Conference**

LYNBROOK, NY – November 24, 2009 - BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming Piper Jaffray 21<sup>st</sup> Annual Health Care Conference on Tuesday, December 1, 2009, at 3:30pm ET at The New York Palace Hotel in New York, NY.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at [www.biospecifics.com](http://www.biospecifics.com), or you may use the link: [http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BSTC&item\\_id=2566242](http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BSTC&item_id=2566242).

### **About BioSpecifics Technologies Corp.**

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for eleven clinical indications, three of which include: Dupuytren's disease, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its partner Auxilium has announced the acceptance of the Biologic License Application and Priority Review by the FDA's Arthritis Advisory Committee for injectable collagenase XIAFLEX in the treatment of Dupuytren's disease, and on September 16, 2009, the Arthritis Advisory Committee unanimously recommended, by a vote of 12 to 0, that the FDA approve XIAFLEX for the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX product in Europe.

### **Contact:**

BioSpecifics Technologies Corp.  
Thomas L. Wegman, President  
(516) 593-7000  
[thomas\\_wegman@biospecifics.com](mailto:thomas_wegman@biospecifics.com)